Altimmune
ALT
173 hedge funds and large institutions have $282M invested in Altimmune in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 40 closing their positions.
54% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $8.07M
13% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 47
13% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 40
1% more funds holding
Funds holding: 172 → 173 (+1)
22.96% less ownership
Funds ownership: 82.78% → 59.83% (-23%)
38% less capital invested
Capital invested by funds: $453M → $282M (-$171M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.1M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$11.2M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$9.55M |
| 4 |
BlackRock
New York
|
+$9.44M |
| 5 |
Capital Fund Management (CFM)
Paris,
France
|
+$6.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$35M |
| 2 |
Millennium Management
New York
|
-$11.6M |
| 3 |
FAM
Fred Alger Management
New York
|
-$10.1M |
| 4 |
Morgan Stanley
New York
|
-$6.8M |
| 5 |
Citigroup
New York
|
-$5.21M |
ALT Hedge Fund Activity: Q2 2024 in Review
173 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q2 2024, worth a combined $282M — down 38% from $453M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ALT positions and 40 closed out — a net gain of 5 holders — while 53 added to existing stakes and 47 trimmed.
The largest buyer was Vanguard Group, adding an estimated $13.1M. The largest seller was State Street, cutting an estimated $35M.
- 173 institutional investors held Altimmune (ALT) as of Q2 2024, up from 172 in Q1 2024.
- Funds reported $282M of Altimmune stock for Q2 2024, down 38% quarter-over-quarter.
- 45 funds opened new Altimmune positions in Q2 2024 and 40 closed out, a net change of +5 holders.
- The largest Altimmune buyer in Q2 2024 was Vanguard Group, an estimated $13.1M added.
- The largest Altimmune seller in Q2 2024 was State Street, an estimated $35M sold.
Based on aggregated 13F filings for Q2 2024.